FDA and EU MDR Regulation of Medical Device Kits, Convenience Kits, and Procedure Packs

Regulating medical device kits, convenience kits, and procedure packs: FDA and EU MDR compared

Assembling several finished medical devices into a single package is one of the most common, and most under-appreciated, regulatory activities in the device industry. A "convenience kit," a custom procedure tray, or an EU "procedure pack" looks like simple bundling, but both FDA and the EU treat the act of combining and, especially, sterilizing components as a manufacturing operation that can carry its own premarket, labeling, and quality obligations. The two systems reach broadly similar outcomes through very different mechanisms: FDA works through the 510(k) framework plus long-standing convenience-kit policy, while the EU relies on the self-contained regime of Article 22 of the Medical Devices Regulation (EU) 2017/745 (MDR). This article maps how each side handles kit definitions, premarket applicability, labeling, sterility, and the combination of already-cleared components.

How each system defines a "kit"

Under FDA rules, a convenience kit is defined for Unique Device Identification (UDI) purposes as "two or more different medical devices packaged together for the convenience of the user," and FDA interprets that to mean devices intended to remain packaged together and not be replaced, substituted, repackaged, sterilized, or otherwise processed or modified before use by the end user ¹⁴⁷¹⁵². That UDI definition is deliberately narrow: FDA states it applies only for UDI purposes, does not define the term for other regulatory purposes, and is not the same as the term used in the 1997 "Convenience Kits Interim Regulatory Guidance" ¹⁴⁷¹⁵². The 1997 guidance itself described most reviewed convenience kits as legally marketed devices simply assembled in kit form for the convenience of the purchaser or user, with additional processing typically limited to outer labeling and terminal sterilization ¹⁶⁹.

The MDR keeps two related concepts distinct. A "procedure pack" is defined in Article 2(10) as a combination of products packaged together and placed on the market for a specific medical purpose ¹³¹. Article 22 then supplies the operative regime for both "systems" and "procedure packs," turning on whether every item carries a CE marking and whether the assembler changes anything about how the components are used or sterilized ¹²⁹.

FDA: when does a kit need its own 510(k)?

FDA's starting point is that kit assembly is not a neutral packaging step. It is a manufacturing activity that can trigger 510(k) obligations if the assembly or reprocessing of the finished kit changes the safety or effectiveness of the components or creates a new intended use ¹⁴⁷¹³⁸. The 2002 "Sterilized Convenience Kits for Clinical and Surgical Use" guidance frames the central question narrowly: the assembler should determine whether sterilization of the kit significantly affects the safety or effectiveness of any component, and if it does, a premarket notification may be needed ¹³⁸.

Where a kit is submitted as a 510(k), FDA's long-standing kit-certification approach requires the assembler to certify that each component is either a legally marketed preamendments device, a device exempt from premarket notification, or a device already found substantially equivalent for the kit's intended use ⁷³. If the assembler cannot make that certification for a component, the component must be itemized and enough information submitted for FDA to evaluate equivalence, which may be the same information needed for a separate 510(k) for that component ⁷³. Components purchased in unfinished or bulk form (rather than final packaged, labeled units) must be identified, and the assembler must describe how the kit is assembled and processed into finished form ⁷³.

Reading FDA's kit and device-modification guidance together, the recurring factors that can push a kit out of "just packaging" and into new-review territory are:

• A new intended use or new indication for a component. The kit certification is available only when the submitter is not claiming or causing a new use for the component(s); a new indication for use is itself a modification that can require a 510(k) ¹².
• A component that is not already legally marketed, exempt, or previously cleared for the kit's intended use, which must then be itemized and reviewed ¹²³¹⁰.
• Bulk or unfinished components requiring further processing such as sterilizing/resterilizing, packaging/repackaging, or labeling/relabeling ²³⁷¹⁰.
• Sterilization or resterilization changes, for which FDA expects a validation study and sterility data consistent with its sterility guidance ⁷.
• Final processing of the kit as a whole that could affect the safety or effectiveness of any component, which is the closest FDA analogue to a concern about chemical or physical interaction among combined items ⁷.

Two policy layers sit on top of this. The 1997 convenience-kits guidance stated that FDA intended to propose rulemaking to exempt certain specifically identified convenience kits from premarket notification, and, pending such a rule, would exercise enforcement discretion regarding premarket clearance for those kits ¹⁶⁹. FDA's 2013 product-code guidance adds the practical listing pathway: before listing a convenience kit, the manufacturer should confirm the kit meets the 1997 convenience-kit criteria, determine whether a matching product code exists, and contact Registration and Listing Staff; if the kit is not one of the established convenience kits, the individual items may instead need to be listed separately under their own 510(k) or exempt product codes ¹⁷⁰.

FDA precedents: combining already-cleared components

The 510(k) record contains a long run of clearances for kits and custom trays built entirely, or almost entirely, from previously cleared, exempt, or preamendments components. Representative examples:

• K072814 — Convenience Kit for Single-Incision Laparoscopic Surgery (Covidien). Combined laparoscopic instruments for access, dissection, hemostasis, and specimen collection; the submission stated materials were unchanged from the predicate devices and relied on multiple named predicates (Endo Clip, Roticulator, AcuClip, Endo Catch Gold, VersaStep Plus trocar, and others) ⁹⁰⁹².
• K970317 — Modified E-Pack Procedure Kit (Ethicon). Combined legally marketed Ethicon finished devices packaged together for surgeon convenience, with the same indication statements as the individually marketed devices ⁹⁹¹¹².
• K964168 — Procedure Specific Kits (Sage Products). Non-sterile kits bundling finished goods that were preamendment, exempt, or already 510(k)-cleared; the sponsor argued that packaging these commonly used devices would not affect safety or effectiveness ⁶².
• K212258 — Medline Cardiovascular Procedure Kit (Medline). Combined single-use sterile drapes and disposable devices that were legally marketed, exempt, or preamendment items, with the predicate being another Medline convenience kit (K962826); the sponsor stated component intended use and design were not altered ⁶¹.
• K152978 — DeRoyal Angiography Kits. Components purchased bulk non-sterile, then assembled, packaged, and sterilized; all components were legally marketed, exempt, cleared, or preamendment, and the sponsor stated the kits did not raise new issues of safety and effectiveness relative to Navilyst and Merit predicate kits ⁶⁶⁶⁷.
• K082164 / K082183 — Pajunk generic convenience trays for regional anesthesia. Trays compiled from devices cleared in prior 510(k)s or exempt; the sponsor stated compliance with FDA's sterilized-convenience-kits guidance ⁶³⁶⁴.
• Medline catheterization and orthopedic trays/kits (K965112, K971208) and similar custom trays assembled to customer specifications from Class I/II devices, drugs, and materials ⁹⁶⁹⁸.

Across these files the substantial-equivalence argument is remarkably consistent. Sponsors frame the product as a convenience assemblage of already legally marketed components, assert that the intended use is unchanged and that the kit "does not cause or promote new intended uses," and compare the kit to an existing convenience-tray predicate with similar contents, materials, packaging, sterilization, and assembly methods ^5960616267. Where the kit adds processing such as sterilization or bonding, sponsors address whether those steps alter safety or effectiveness, with the common conclusion that they do not provided validation supports it ^62636467.

Importantly, FDA has used clearance correspondence to underscore the limits of the convenience-kit shortcut. In the Pajunk file, FDA's letter explicitly reminded the sponsor that it is responsible for ensuring each component has its own proper regulatory status, and that if components are purchased in bulk and further processed, a new 510(k) may be needed ⁶⁵. That caveat is the practical hinge for anyone relying on the convenience-kit pathway.

FDA: labeling of kits

Kit labeling turns on whether the product qualifies as a convenience kit and on whether it is sterile or contains relabeled/repackaged devices. For UDI, the label and each device package of a medical device generally must bear a UDI, but 21 CFR 801.30(a)(11) provides an exception for devices inside the immediate container of a convenience kit when the kit label itself bears a UDI ¹⁵²¹⁵⁸. That exception is permissive, not prohibitive: an assembler may still place UDIs on the individual devices ¹⁵⁷. If devices in the kit are intended to be reprocessed/reused, or the kit requires sterilization before use, the package may not qualify as a convenience kit, and each device must then meet applicable UDI labeling, data-submission, and direct-mark requirements ^136147148.

For sterility claims, FDA's labeling guidance is explicit that multi-device kits or packages containing a combination of sterile and nonsterile products must not state or imply that all contents are sterile ¹⁴⁰. Labeling should accurately state what is sterile and, where users must sterilize or resterilize, should provide adequate information on suitable methods, special cleaning, physical changes from reprocessing, and limits on resterilization or reuse ¹⁴⁰. FDA also expects assemblers to confirm that expiration dates on kit labeling are valid and that storage instructions are validated, and to consider the impact of sterilization on expiration dating and shelf life ¹⁴⁴¹³⁷. Throughout, the assembler/manufacturer is responsible for correct labeling and for ensuring components are not adversely affected by further processing, with assembly and sterilization treated as manufacturing operations subject to GMP requirements ¹³⁸¹⁴⁵.

FDA: sterility and shelf life

For any component or kit sold sterile, FDA expects information on the sterilization method, the method used to validate the cycle, the sterility assurance level (SAL), and a description of packaging that maintains sterility, plus a description of how the kit is assembled and processed into finished form; where a component is reprocessed or resterilized, a validation study with data is expected ⁷. Sterility testing at the initial time point alone is not sufficient to demonstrate container-closure integrity over the shelf life ¹³. Radiation sterilization should be validated in accordance with ANSI/AAMI/ISO 11137 ¹⁶, and for established sterilization methods FDA generally does not require the validation data itself to support substantial equivalence, though the validation method must be identified ²⁴.

Shelf-life claims should be supported by package-integrity and/or device-performance testing that includes simulated distribution and simulated and/or real-time aging, plus seal-strength testing, following ISO 11607-1 and ISO 11607-2 for packaging validation ^1415172225. Where accelerated aging is used, FDA expects a rationale that it is representative of real-time aging, and for polymeric materials and coatings, real-time aged samples should confirm the accelerated-aging results ^1517222425.

EU MDR: Article 22 systems and procedure packs

The MDR consolidates the entire kit question into Article 22, which splits into two fundamentally different tracks.

Track 1 - a compliant combination of CE-marked items. A natural or legal person may combine CE-marked devices (and CE-marked IVDs or other products lawfully placed on the market and used within a medical procedure) into a system or procedure pack and draw up a statement, provided the combination is compatible with the manufacturers' intended purposes and stays within their limits of use ¹²⁹. In that statement the assembler declares that it verified mutual compatibility according to the manufacturers' instructions and acted accordingly, packaged the pack and supplied users with the relevant information including the manufacturers' information, and subjected the combining activity to appropriate internal monitoring, verification, and validation ¹²⁹. Crucially, a Track 1 pack does not bear an additional CE marking, but it must bear the assembler's name, registered trade name or trademark and a contact address, be accompanied by the information in Section 23 of Annex I, and the statement must be kept available to competent authorities ¹²⁹.

Track 1a - sterilization by the assembler (Article 22(3)). If the assembler sterilizes a Track 1 pack for placing it on the market, it must apply one of the conformity assessment procedures in Annex IX or the procedure in Part A of Annex XI, with the notified body's involvement limited to the aspects relating to ensuring sterility until the sterile packaging is opened or damaged, and it must draw up a statement that sterilization was carried out in accordance with the manufacturer's instructions ¹²⁹. This is the one place a notified body routinely enters the picture for an otherwise self-declared pack.

Track 2 - the pack becomes a device in its own right (Article 22(4)). If the pack incorporates devices that do not bear a CE marking, if the combination is not compatible with the components' original intended purpose, or if sterilization has not been carried out in accordance with the manufacturer's instructions, the pack is treated as a device in its own right and must undergo the relevant conformity assessment procedure under Article 52, and the assembler assumes the full obligations of a manufacturer ¹²⁹.

EU MDR: registration, UDI, and labeling for packs

For a Track 1 or Track 1a pack, the responsible person must assign a Basic UDI-DI before placing the pack on the market and provide it to the UDI database with the other core data elements ¹³⁴, and is responsible for identifying the pack with a UDI comprising both a UDI-DI and UDI-PI ¹³²¹³⁵. MDCG guidance fleshes out the operational duties. MDCG 2018-3 rev.1 (UDI for systems and procedure packs), supported by MDCG 2018-4, is the primary reference ^40414344. The "system or procedure pack producer" must register and obtain a Single Registration Number (SRN), and the pack must undergo UDI registration under Article 29(2) MDR, with the UDI database entry capturing the Basic UDI-DI, medical purpose, producer identity and SRN, risk class, and flags for whether the pack is labeled sterile or requires sterilization before use ⁴³⁴⁴⁴⁷. The UDI carrier is placed on the label or packaging of the entire pack, generally on the outside of the packaging, per Article 22(5) and Annex VI ⁴²⁵¹. Where Track 2 applies, the person combining the products assumes manufacturer obligations, including the manufacturer-level UDI and Basic UDI-DI labeling duties ³⁹⁴⁶⁵¹.

On sterile labeling specifically, MDR Annex I, Chapter III, Section 23.2 requires the label to indicate, where the device is supplied sterile, its sterile state and the sterilization method, and to indicate single-use status where applicable ¹⁶⁴. Section 23.1 governs the medium, format, legibility, and location of the label and instructions for use, allows required information to appear on the device, packaging, or IFU as appropriate, and permits internationally recognized symbols ¹⁶⁴. Annex VI, Part B additionally requires the UDI database to record whether the device is labeled single-use, any maximum number of reuses, whether it is labeled sterile, and whether sterilization before use is needed ¹⁶⁶.

FDA and MDR side by side

Practical takeaways for regulatory affairs

Both regimes reward the same discipline: document each component's regulatory status, confirm the combination does not create a new intended use, and treat sterilization as the highest-risk step. In the US, the convenience-kit pathway is real but conditional, and FDA has repeatedly reminded assemblers that they own component status and that bulk-and-further-process workflows can require a fresh 510(k) ⁶⁵. In the EU, the analysis reduces to a single question chain under Article 22: are all items CE-marked, is the combination within their intended purposes, and is any sterilization done per the manufacturers' instructions. A "no" to any of these converts the pack into a device requiring Article 52 conformity assessment and full manufacturer obligations ¹²⁹. For a global kit strategy, the practical divergence points worth a deeper follow-up are sterilization-driven notified body involvement under Article 22(3), the UDI/EUDAMED registration mechanics for pack producers, and how FDA's UDI convenience-kit definition interacts with the older 1997 and 2002 policies for products that fall outside the narrow UDI definition.